M. Pfreundschuh

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.

Jens Atzpodien, E Lopez Hänninen, H. Kirchner et al. · Journal of Clinical Oncology · 1995 · 142 citations

Medicine, Oncology, Pharmacotherapy +16

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.

Markus Loeffler, Volker Diehl, M. Pfreundschuh et al. · Journal of Clinical Oncology · 1997 · 86 citations

Medicine, Oncology, Radiation Oncology +10

High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma

Marita Ziepert, Marcel Reiser, Mathias Freund et al. · Annals of Oncology · 2010 · 37 citations · Full text

Medicine, Hematology, Oncology +12

Anti- CD16/CD30 Bispecific Antibodies as Possible Treatment for Refractory Hodgkin's Disease

Frank Hartmann, Christoph Renner, Wolfram Jung et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1998 · 29 citations

Life Sciences, Immunology, Oncology +17